http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022211376-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_113001f16b5885d43803e02dd4c831cd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0786 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2022-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ae895b66a61064083a3e82032b23f0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53f61230d7d9bd95c897d0e45bbee048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ca7c5443ab1734a8a501e03fd99d739 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_638b2c8e587487939692f89c3176cb58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2834f6f51748a38faf6e4a7c4958c944 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fb5155af7f89cc94a0d95cbbfa52d07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9174744e71b31d684b9874fd278b1278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9874f757fd39ada672edefbebbe411d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b172594d7beb17a5cf022290a5ef72f |
| publicationDate | 2022-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022211376-A1 |
| titleOfInvention | Transformed antigen-specific professional antigen presenting cells comprising chimeric antigen receptor (car) and use thereof |
| abstract | The present invention relates to transformed antigen-specific professional antigen presenting cells comprising a chimeric antigen receptor (CAR), and more particularly, to a cell therapy product or a pharmaceutical composition for treating cancer comprising the cells as an active ingredient, wherein the chimeric antigen receptor includes an antigen-binding domain which specifically binds to programmed death-ligand 1 (PD-L1). The transformed cells according to the present invention provide a reinforced chimeric signaling domain, which induces the activity of professional antigen presenting cells, when the professional antigen presenting cells specifically bind to an antigen. For example, the professional antigen presenting cells transformed via a vector capable of overexpressing a recombinant protein including a signal transduction domain in a novel synthetic cell have cytotoxicity specific to carcinomas expressing PD-L1, the recombinant protein being a protein in which a dimer, in which a pair of extracellular domains of PD1 are each linked to a human immunoglobulin G 1 (IgG 1 ) heavy chain constant region, and an immunoreceptor tyrosine-based activation motif (ITAM) of a TLR-3, a TLR-4, and an IgE receptor gamma chain (Fcε receptor I gamma chain, FcεRIγ), an IgG receptor 2A alpha chain (Fcγ receptor 2A alpha chain, FcγR2Aα) or an IgE receptor beta chain Fcε receptor I beta chain, FcεRIβ), which play an important role in the signal transduction of the professional antigen presenting cells, are subunits, and three ITAMs are linked by a linker. Therefore, the professional antigen presenting cells overexpressing the chimeric antigen receptor according to the present invention can be useful as an immune cell therapy product for treating carcinomas expressing PD-L1. |
| priorityDate | 2021-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 135.